Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- AZ/Fujifilm Develop Chemoradiotherapy Database for Lung Cancer
April 10, 2024
- Hypertension Therapy App Might Reduce Use of Antihypertensives: CureApp
April 10, 2024
- Otsuka/Lundbeck Seek PTSD Nod for Rexulti in US
April 10, 2024
- US FDA Grants Orphan Exclusivity for ALS Drug Radicava ORS
April 10, 2024
- R&D Jobs Make Up 40% of Pharma New Grads Hires This Spring, Sales Reps Only 20%: Poll
April 9, 2024
- Toray Nets Positive Preclinical Data in Polymer-Conjugated Cancer Drug
April 9, 2024
- Renalys Submits IND for Japan PIII Study of IgA Nephropathy Drug
April 9, 2024
- Janssen Files Amivantamab Plus Lazertinib for NSCLC in Japan
April 9, 2024
- Enhertu Nabs Pan-Tumor Indication in US: Daiichi Sankyo
April 9, 2024
- GSK Japan Shooting for 80% Goal for Paid Paternity Leave in 2024
April 8, 2024
- Otsuka, Verily Join Forces to Run Mental Health Registry
April 8, 2024
- Japan Ethical Drug Sales Zoom 12.1% in February: Crecon
April 8, 2024
- Keytruda Tops Japan Sales List for 6th Month in March: Encise
April 8, 2024
- Kyowa Kirin Hopes Amgen-Partnered Eczema Drug to Rival or Even Eclipse Crysvita in Sales: CEO
April 5, 2024
- Rohto, Mitsui to Buy Singapore’s Chinese Medicine Firm for SGD800 Million
April 5, 2024
- Nippon Shinyaku, MiNA Therapeutics Join Hands in Rare CNS Disorders
April 5, 2024
- Healios Snaps Up Assets after Athersys’ Bankruptcy Filing
April 5, 2024
- Tarlige Winner in February GP Rep Promotion Rankings
April 4, 2024
- Taisho’s Positive PIII Data Set Stage for Japan Filing of Insomnia Med
April 4, 2024
- FDA OKs First Digital Therapeutic App for Depression: Otsuka
April 4, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…